IN2012DN02782A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02782A IN2012DN02782A IN2782DEN2012A IN2012DN02782A IN 2012DN02782 A IN2012DN02782 A IN 2012DN02782A IN 2782DEN2012 A IN2782DEN2012 A IN 2782DEN2012A IN 2012DN02782 A IN2012DN02782 A IN 2012DN02782A
- Authority
- IN
- India
- Prior art keywords
- antagonist
- beta
- patient
- side effects
- comprises administering
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24938609P | 2009-10-07 | 2009-10-07 | |
| PCT/US2010/050328 WO2011043942A1 (en) | 2009-10-07 | 2010-09-27 | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02782A true IN2012DN02782A (zh) | 2015-09-18 |
Family
ID=43857059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2782DEN2012 IN2012DN02782A (zh) | 2009-10-07 | 2010-09-27 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120202819A1 (zh) |
| EP (1) | EP2485595A4 (zh) |
| JP (1) | JP5738871B2 (zh) |
| KR (1) | KR20120093859A (zh) |
| CN (1) | CN102638987A (zh) |
| AU (1) | AU2010303811B2 (zh) |
| BR (1) | BR112012007829A2 (zh) |
| CA (1) | CA2774992A1 (zh) |
| IL (1) | IL218756A0 (zh) |
| IN (1) | IN2012DN02782A (zh) |
| MX (1) | MX2012004134A (zh) |
| NZ (1) | NZ599233A (zh) |
| RU (1) | RU2012118668A (zh) |
| WO (1) | WO2011043942A1 (zh) |
| ZA (1) | ZA201202520B (zh) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20131341A1 (es) * | 2010-08-03 | 2013-12-07 | Altherx Inc | Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| MX348723B (es) * | 2011-05-10 | 2017-06-27 | Theravida Inc | Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| JP6063948B2 (ja) | 2011-10-27 | 2017-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ベータ３アゴニストおよび中間体を製造するプロセス |
| CN104684549A (zh) * | 2012-02-09 | 2015-06-03 | 奥瑟克斯公司 | 治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合 |
| DK2968269T3 (da) * | 2013-03-15 | 2019-10-07 | Merck Sharp & Dohme | Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter |
| CA2919198A1 (en) * | 2013-07-23 | 2015-01-29 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist |
| EP3220942B1 (en) | 2014-11-20 | 2022-04-27 | Serenity Pharmaceuticals LLC | Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist |
| KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| FI3365321T3 (fi) | 2015-10-23 | 2024-01-02 | B3Ar Therapeutics Inc | Solabegron-Zwitterioni ja sen käyttöjä |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| AU2018282104B2 (en) | 2017-06-06 | 2024-07-11 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
| CA3085745A1 (en) * | 2017-12-21 | 2019-06-27 | Kyorin Pharmaceutical Co., Ltd. | An agent for treating nocturnal pollakiuria |
| CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789076B1 (fr) * | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| WO2003024483A1 (fr) * | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| CA2580170A1 (en) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| AU2008233232A1 (en) * | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2010
- 2010-09-27 MX MX2012004134A patent/MX2012004134A/es not_active Application Discontinuation
- 2010-09-27 BR BR112012007829A patent/BR112012007829A2/pt not_active IP Right Cessation
- 2010-09-27 RU RU2012118668/13A patent/RU2012118668A/ru not_active Application Discontinuation
- 2010-09-27 US US13/500,574 patent/US20120202819A1/en not_active Abandoned
- 2010-09-27 CA CA2774992A patent/CA2774992A1/en not_active Abandoned
- 2010-09-27 IN IN2782DEN2012 patent/IN2012DN02782A/en unknown
- 2010-09-27 CN CN2010800550891A patent/CN102638987A/zh active Pending
- 2010-09-27 NZ NZ599233A patent/NZ599233A/xx not_active IP Right Cessation
- 2010-09-27 EP EP10822429.6A patent/EP2485595A4/en not_active Withdrawn
- 2010-09-27 JP JP2012533204A patent/JP5738871B2/ja active Active
- 2010-09-27 KR KR1020127008961A patent/KR20120093859A/ko not_active Application Discontinuation
- 2010-09-27 AU AU2010303811A patent/AU2010303811B2/en not_active Ceased
- 2010-09-27 WO PCT/US2010/050328 patent/WO2011043942A1/en active Application Filing
-
2012
- 2012-03-20 IL IL218756A patent/IL218756A0/en unknown
- 2012-04-05 ZA ZA2012/02520A patent/ZA201202520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ599233A (en) | 2013-04-26 |
| AU2010303811A1 (en) | 2012-04-19 |
| EP2485595A1 (en) | 2012-08-15 |
| CN102638987A (zh) | 2012-08-15 |
| JP2013507363A (ja) | 2013-03-04 |
| CA2774992A1 (en) | 2011-04-14 |
| WO2011043942A1 (en) | 2011-04-14 |
| ZA201202520B (en) | 2012-12-27 |
| EP2485595A4 (en) | 2014-03-12 |
| BR112012007829A2 (pt) | 2015-09-22 |
| RU2012118668A (ru) | 2013-11-20 |
| US20120202819A1 (en) | 2012-08-09 |
| AU2010303811B2 (en) | 2013-01-24 |
| JP5738871B2 (ja) | 2015-06-24 |
| IL218756A0 (en) | 2012-06-28 |
| KR20120093859A (ko) | 2012-08-23 |
| MX2012004134A (es) | 2012-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02782A (zh) | ||
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| BR112012025017A2 (pt) | métodos para melhorar a qualidade do sono. | |
| AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| UA111959C2 (uk) | Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом | |
| MX2010005331A (es) | Composiciones y metodos para tratamiento de purpura. | |
| MX2009011898A (es) | Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. | |
| HK1140141A1 (en) | Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| BR112012022064A2 (pt) | tratamento de artrite lúpica usando laquinimod | |
| WO2009129432A3 (en) | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation | |
| MY165160A (en) | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS | |
| MX354125B (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
| WO2009129494A3 (en) | Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| MX353105B (es) | Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva. | |
| MX2013008729A (es) | Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. | |
| EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
| EP2263705A4 (en) | THERAPEUTIC AGENT AGAINST NERVE INJURY AND METHOD FOR TREATING NERVE INJURY | |
| WO2009052073A3 (en) | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists | |
| TN2011000457A1 (en) | Method or system using biomarkers for the monitoring of a treatment | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2009009332A (es) | Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis. | |
| WO2009052075A3 (en) | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |